Dectrekumab/VAK 694

Drug Profile

Dectrekumab/VAK 694

Alternative Names: QAX-576/VAK-694; QBX-258; VAK-694/dectrekumab; VAK-694/QAX-576

Latest Information Update: 25 Jan 2016

Price : $50

At a glance

  • Originator Novartis
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma

Most Recent Events

  • 30 Jul 2015 Dectrekumab/VAK 694 is still in phase II trials for Asthma in the USA
  • 01 Feb 2012 Phase-II clinical trials in Asthma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top